Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro
Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...
inews.co.uk on MSN6h
Why the viral £50 Mounjaro 'dose hack' could be dangerous
Mounjaro weight-loss injection pens should contain four doses, but some users are managing to get a fifth dose out of the devices. Experts are warning against this ...
Jim Cramer Says You Should ‘Stay Long’ Eli Lilly (LLY) Because of These Reasons
Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...
Fierce Healthcare1d
DTC obesity med market heats up: Eli Lilly taps knownwell, Hims & Hers adds new weight loss meds to platform
Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...
Eli Lilly sues Strive and Empower as FDA lifts tirzepatide shortage status
Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.
CNBCTV1811d
Eli Lilly’s Mounjaro targets India’s $150 billion weight-loss market amid rising diabetes crisis
Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...
Where Will Eli Lilly Be in 1 Year?
Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...
Eli Lilly Vs. Hims & Hers In DTC Weight Loss Market? - There Is Only One Winner
Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.